IMNM vs STRO
IMNM: A clinical-stage oncology biotech advancing first-in-class and best-in-class targeted cancer therapies, including varegacestat for desmoid tumors and a pipeline of antibody-drug conjugates for solid tumors and hematologic malignancies. STRO: Sutro Biopharma is a clinical-stage oncology firm using proprietary cell-free protein synthesis technology to develop specialized antibody-drug conjugates for cancer treatment.
Side-by-side fundamentals
| Metric | IMNM | STRO | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $22.88 | $23.40 | |
| Market cap as of 2026-07-23 | $2.6B | $388M | |
| Net margin as of 2026-07-23 | -1687.1% | -154.2% | STRO higher |
| Operating margin as of 2026-07-23 | -1784.1% | -120.0% | STRO higher |
| ROE as of 2026-07-23 | -51.1% | -223.8% | IMNM higher |
| ROA as of 2026-07-23 | -47.3% | -69.2% | IMNM higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | -63.3% | +49.9% | STRO higher |
| Revenue CAGR (3y) SEC XBRL | -29.6% | +14.8% | STRO higher |
| Beta as of 2026-07-23 | 2.11 | 1.50 | |
| 1-year return as of 2026-07-22 close | +110.5% | +173.0% | STRO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.